MNLO - メンロ―・セラピュ―ティクス (Menlo Therapeutics Inc.)

MNLOのニュース

   Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics  2020/09/08 12:01:00 PR Newswire
BRIDGEWATER, N.J., Sept. 8, 2020 /PRNewswire/ -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from "MNLO" to "VYNE"….
   This Analyst Thinks Menlo (MNLO) Stock Is Poised for Growth  2020/06/02 16:40:18 Yahoo Finance
2020 has been kind to small-cap biotechs. Some have spiked upwards dramatically this year, mostly on the hope of finding solutions to COVID-19, be it a treatment or vaccine. Those who haven’t gotten in on the action yet still yearn to join the fray, might justifiably feel a sense of apprehension. An
   Menlo Therapeutics (MNLO) Catches Eye: Stock Jumps 7.1%  2020/05/27 12:43:00 Zacks Investment Research
Menlo Therapeutics (MNLO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
   Menlo Therapeutics Inc (MNLO) Reports Q1 Loss, Lags Revenue Estimates  2020/05/11 13:05:03 Zacks Investment Research
Menlo Therapeutics Inc (MNLO) delivered earnings and revenue surprises of -90.00% and -20.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Menlo Therapeutics Inc. (MNLO) Shares March Higher, Can It Continue?  2020/05/06 13:56:52 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Menlo Therapeutics Inc. (MNLO).
   This Analyst Thinks Menlo (MNLO) Stock Is Poised for Growth  2020/06/02 16:40:18 Yahoo Finance
2020 has been kind to small-cap biotechs. Some have spiked upwards dramatically this year, mostly on the hope of finding solutions to COVID-19, be it a treatment or vaccine. Those who haven’t gotten in on the action yet still yearn to join the fray, might justifiably feel a sense of apprehension. An
   Menlo Therapeutics (MNLO) Catches Eye: Stock Jumps 7.1%  2020/05/27 12:43:00 Zacks Investment Research
Menlo Therapeutics (MNLO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
   Menlo Therapeutics Inc (MNLO) Reports Q1 Loss, Lags Revenue Estimates  2020/05/11 13:05:03 Zacks Investment Research
Menlo Therapeutics Inc (MNLO) delivered earnings and revenue surprises of -90.00% and -20.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   Menlo Therapeutics Inc. (MNLO) Shares March Higher, Can It Continue?  2020/05/06 13:56:52 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Menlo Therapeutics Inc. (MNLO).
   Menlo (MNLO) in Focus: Stock Moves 9.9% Higher  2020/04/24 12:53:00 Zacks Investment Research
Menlo (MNLO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
   Menlo Therapeutics Inc. (MNLO) Shares March Higher, Can It Continue?  2020/05/06 13:56:52 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Menlo Therapeutics Inc. (MNLO).
   Menlo (MNLO) in Focus: Stock Moves 9.9% Higher  2020/04/24 12:53:00 Zacks Investment Research
Menlo (MNLO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
   SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.  2019/11/12 22:09:00 Benzinga Feeds
NEW YORK , Nov. 12, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Foamix Pharmaceuticals Ltd. ("FOMX" or the "Company") (NASDAQ: FOMX ) in connection with the proposed acquisition of the Company by Menlo Therapeutics, Inc. ("MNLO") (NASDAQ: MNLO ). Under the terms of the acquisition agreement, FOMX shareholders will receive 0.5924 shares of MNLO and a contingent stock right for each FOMX share they own. If you own FOMX shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: http://www.weisslawllp.com/foamix-pharmaceuticals-ltd/ Full story available on Benzinga.com
   Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study  2019/09/25 17:18:00 Zacks Investment Research
Menlo (MNLO) completes enrollment in the phase II study evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of CPUO.
   The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering  2019/08/06 11:22:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.

calendar